🔴 Warren Buffett's Berkshire Hathaway takes a $1.6 Billion position in UnitedHealth $UNH
Disclaimer
This marketing document has been issued by Bank Syz Ltd. It is not intended for distribution to, publication, provision or use by individuals or legal entities that are citizens of or reside in a state, country or jurisdiction in which applicable laws and regulations prohibit its distribution, publication, provision or use. It is not directed to any person or entity to whom it would be illegal to send such marketing material. This document is intended for informational purposes only and should not be construed as an offer, solicitation or recommendation for the subscription, purchase, sale or safekeeping of any security or financial instrument or for the engagement in any other transaction, as the provision of any investment advice or service, or as a contractual document. Nothing in this document constitutes an investment, legal, tax or accounting advice or a representation that any investment or strategy is suitable or appropriate for an investor's particular and individual circumstances, nor does it constitute a personalized investment advice for any investor. This document reflects the information, opinions and comments of Bank Syz Ltd. as of the date of its publication, which are subject to change without notice. The opinions and comments of the authors in this document reflect their current views and may not coincide with those of other Syz Group entities or third parties, which may have reached different conclusions. The market valuations, terms and calculations contained herein are estimates only. The information provided comes from sources deemed reliable, but Bank Syz Ltd. does not guarantee its completeness, accuracy, reliability and actuality. Past performance gives no indication of nor guarantees current or future results. Bank Syz Ltd. accepts no liability for any loss arising from the use of this document.
Related Articles
Many of the industry’s biggest cash-generating drugs will lose exclusivity this decade. Novo Nordisk could see 77% of its 2025 sales exposed by 2033, while Keytruda—a $32 billion blockbuster—is set to lose patent protection before 2030. Once generics and biosimilars enter the market, revenues can collapse within just a few years. The industry’s response? Buy growth. Pharmaceutical companies announced $114 billion of deals last quarter—the highest level since 2019. That wave of M&A is driving capital into biotech, helping the sector gain more than 30% this year. With $440 billion of revenue potentially at risk, Big Pharma’s race to replenish its pipeline is creating a powerful bid for takeover targets across the biotech sector. Source: Kurt S. Altrichter, CRPS®
David Einhorn -4.1% Cathie Wood -4.6% Warren Buffett -11.0% Bill Ackman -13.4% Carl Icahn -22.0% Michael Saylor -31.6% Source: AskLivermore
This is double the previous reports last week of 1,000 trillion won ($650B). Source: Negligible Capital @negligible_cap Bloomberg

